Straight-talking financial adviser for business owners and senior professionals 👨🏻‍💼 Jargon-free financial advice and planning without the pinstripe suit 😎 Do you know how much you’ll have to live on in retirement?

Your company stock is worth more than your house.

On paper, you're wealthy. In reality? You're terrified of having all your eggs in one very expensive basket.

I get it.

As one client put it: "If you talk to people who worked at Nokia or Blackberry, you know that rich feeling can flip very quickly."

I'm Shabbar. I've spent 15+ years helping professionals just like you turn financial complexity into life clarity.

Here's what I believe: Money is never the end goal. It's the tool that gives you choices.

Whether you're wrestling with RSU golden handcuffs or wondering "When can I actually retire?", the questions that keep you awake aren't really about money. They're about life:

- What lifestyle do I want when I retire and how much will this cost?
- How much should I be saving for my retirement?
- When can I afford to stop working, slow down, or perhaps work part-time?
- What income can I expect from my various pension plans?

My approach is different. I don't start with your portfolio - I start with your life.

What makes me different with RSUs specifically?

I help you diversify smartly - reducing concentration risk while still backing your company to succeed. We explore strategies like utilising spouse allowances, maximising available tax vehicles, and creating a balanced approach that doesn't leave you overexposed to one stock's performance.

The result?

Take one recent client - a senior professional whose RSU grants had grown to over 50% of their net worth. They felt wealthy on paper but terrified about having everything tied to one company.

Within 18 months, we'd reduced their company stock exposure to just 7% while building a diversified, tax-efficient portfolio. We used both spouses' CGT allowances, timed sales around vesting dates to avoid unnecessary tax, and wrapped the proceeds in ISAs and pension contributions.

Now they sleep better, have genuine diversification, and still benefit from their company's success - just without the anxiety of having all their eggs in one basket.

Ready to stop feeling trapped by your own success?

Shabbar Kassam

Cumulus Oncology

I am delighted to join the Advisory Board of Cumulus Oncology. This is an exciting time for oncology drug development and Cumulus offers the opportunity to bring the latest cutting edge science into clinical development by creating and managing spin-out companies specifically targeted at developing novel anti-cancer treatments.

Member Of Advisory Board

MRD Pharma Consultancy Limited

I’m delighted to inform all my connections on Linked In that, I have recently started my own consultancy business. MRD Pharma Consultancy Limited offers a range of oncology-focused services within clinical development and medical affairs.
You can find out more at our website www.mrdpharma.com
Please feel free to get in touch via email [mrd@mrdpharma.com] or via ‘Linked In’

Senior Director & Principal

AstraZeneca

Senior Global Medical Affairs Leader - Oncology

Novartis

I became part of Novartis Oncology following the completion of the acquisition of GSK Oncology by Novartis. I continued to support Votrient (Pazopanib) for both RCC & STS indications.

Snr Director - Clinical Development Oncology - Global Medical Affairs

GlaxoSmithKline

Member of the Votrient Global Medical Team supporting global medical activities for the soft tissue sarcoma indication. I also support Votrient medical teams for Asia Pac / Emerging Markets / Japan.

Director - Oncology Global Medical Affairs

Votrient™ (Pazopanib) Clinical indication leader for Sarcoma and clinical lead for the Phase III (PALETTE) study team. The successful Phase III study was recently published in the Lancet - http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60651-5/abstract

Throughout 2009 I worked for Oncology R&D in the APJEM (Asia Pacific - Japan - Emerging Markets) team, and returned to PALETTE team in 2010.

Director / Clinical Leader

Pfizer Global Research & Development

Clinical Leader for 2 of Pfizer's oncology development programmes.

Director/Clinical Leader - Oncology

Agouron Pharmaceuticals Inc

Managed Global studies (ex-US) for Agouron in oncology & HIV.
Head of Agouron's UK based international clinical operations group

Associate Director - International Clinical Research

Akos Clinical Development

Contract research house: Managed oncology development programmes on behalf of clients (worked extensively with Japanese Pharma).

Senior Clinical Manager - Oncology & Biotherapeutics

US Bioscience

Oncology Group Leader

Bristol Myers Squibb

International Clinical Cancer Research Team

Clinical Scientist

Over the course of his career to date, Mohamed (Raz) has held roles of increasing seniority and made significant leadership contributions to six oncology drug approvals and launches for various cancer treatment settings: Taxol [Bristol-Myers Squibb]; Amifostine [US Bioscience]; Sunitinib & Axitinib [Pfizer Oncology]; Pazopanib [GSK Oncology]; Osimertinib [AstraZeneca Oncology]. 
Mohamed currently works as a global pharmaceutical consultant within the oncology therapeutic area [mrdpharma.com]

Summary of Relevant Experience:

  More than 30 years of international pharmaceutical industry expertise in oncology clinical development and global medical affairs

  Strategic development and trial design & execution across all phases of oncology drug development, taking molecules from first in human to registration and Phase IV (experience includes taxanes, monoclonal antibodies, novel biologics, TKIs’ and cytoprotective agents)
  Management of global clinical trials in lung, breast; genitourinary; gastrointestinal and other solid tumours
  Broad oncology experience, in both exploratory and late-stage clinical development within large and speciality pharma companies and global medical affairs activities spanning all international markets (including Japan, and Asia / Pacific region).
  Global team leadership within a highly matrixed environment.

Mohamed is a highly experienced and talented oncology professional with broad strategic, development and regulatory expertise that spans across clinical development and medical affairs (including ‘real-world evidence’ and medical education). He has extensive global experience working for European and US-headquartered biopharmaceutical companies.
Past pharma employers:
Celltech Limited; BMS International (Brussels); US Bioscience (Philadelphia); Agouron Pharmaceuticals Inc (San Diego); Pfizer Oncology (Sandwich & Milano); GSK Oncology (Brentford UK); AstraZeneca Oncology (Cambridge UK).

taplio

The Battle

Shabbar Kassam

Mohamed Dewji

Followers

Posts

Engagements

Likes

Ready to grow your LinkedIn presence?